Roche's CT-388 dual incretin obesity asset offers a credible Phase 3 entry into the GLP-1 category by 2027. Vabysmo continues to take retina share from Eylea HD. Diagnostics division benefits from continued companion diagnostic demand as oncology personalizes. Pipeline depth is among industry-best with multiple late-stage Alzheimer's and oncology assets.
Thesis reviewed May 29, 2026
Roche Holding AG is headquartered in Switzerland, which is currently showing moderate signals.
π¨πSwitzerland48NEUTRALView Switzerland risk detail βπPharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 50 | +24% | β0% | EARLY |
| AZN | AstraZeneca PLC | 50 | +11% | β0% | EARLY |
| SNY | Sanofi | 50 | +14% | β0% | EARLY |
| GSK | GSK plc | 50 | +8% | β0% | NEUTRAL |
| PFE | Pfizer Inc. | 50 | +6% | β0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | β0% | EARLY |
| RDY | Dr Reddy's Laboratories Ltd | 50 | +7% | β0% | NEUTRAL |
Investors who hold RHHBY may also have indirect exposure through these country funds.
CT-388 Phase 2 shows 18% weight loss with weekly dosing
Vabysmo extended interval Q16 data extends durability lead
Roche diagnostics wins major NHS contract for companion testing
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Josh GottheimerNJ | D | Buy | $1kβ$15k | Jul 23, 24 | +38.3% |
| Josh GottheimerNJ | D | Sell | $1kβ$15k | Jun 21, 24 | +63.1% |